Lot KLO432 Save $42.50 KLOW Blend 80mg Research Peptides

Research peptide · Lyophilized

KLOW Blend 80mg Research Peptides

KLOW Blend — USA Made, ≥99% Purity

4.9 177 verified reviews

80mg four-component blend: GHK-Cu 50mg + BPC-157 10mg + TB-500 10mg + KPV 10mg
USA manufactured in GMP-certified California and Arizona laboratory facilities
≥99% component purity target with HPLC, mass spectrometry, and combined batch COA

$169.99 $212.49 Save $42.50

Manufactured in a GMP facility · Independently tested · Batch COA

Dispatched from a US warehouse within 48 hours, tracked

Certificate of analysis for lot KLO432 below

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Specifications

Lot KLO432

Purity target

≥99%

≥99% per peptide component (3rd-Party HPLC Tested)

Components

GHK-Cu: 402.92; BPC-157: 1,419.5; TB-500: 889.01; KPV: 342.43 g/mol

Vial content

80 MG

Lyophilized Powder

Sequences

GHK-Cu: GHK·Cu²⁺; BPC-157: GEPPPGKPADDAGLV; TB-500: Ac-LKKTETQ; KPV: Lys-Pro-Val

CAS: GHK-Cu: 89030-95-5; BPC-157: 137525-51-0; TB-500: 885340-08-9; KPV: 67727-97-3
Molecular mass: GHK-Cu: 402.92; BPC-157: 1,419.5; TB-500: 889.01; KPV: 342.43 g/mol
Purity target: ≥99% per peptide component (3rd-Party HPLC Tested)
Form: Lyophilized Powder
Origin: Manufactured, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is KLOW Blend?

KLOW Blend is an 80mg research formulation containing GHK-Cu 50mg plus 10mg each of BPC-157, TB-500, and KPV. The vial brings together four distinct peptide structures spanning copper coordination, vascular signaling, an actin-binding fragment, and an alpha-MSH-derived tripeptide.

This is a co-formulated research blend, not a newly bonded 80mg molecule. Its value in the laboratory is the ability to observe several independent signaling routes under the same controlled experimental conditions.

How It Works

Matrix and copper signaling: GHK-Cu is studied in copper transport, fibroblast activity, and extracellular-matrix remodeling.

Vascular and cytoskeletal signaling: BPC-157 research examines VEGFR2/Akt/eNOS pathways, while TB-500 represents an actin-binding motif.

Inflammatory-pathway signaling: KPV is studied for PepT1 transport and modulation of NF-κB and MAPK responses in preclinical models.

Analytical data

Every lot, on the record

Independent third-party HPLC evaluates the purity target, while mass spectrometry confirms molecular identity. Both results are documented in one combined, batch-specific Certificate of Analysis.

Purity (HPLC-UV)

99.78%

Net content

GHK-Cu - 55.24 mg KPV - 10.78 mg BPC-157 - 10.24 mg Thymosin Beta-4 - 10.58 mg

Reported

2026-06-01

Identity (LC-MS): Confirmed
Appearance: Blue Lyophilized Powder

HPLC MS

Analyte	Method	Result
Identity	LC-MS	GHK-Cu/KPV/Thymosin Beta-4/BPC-157
Purity	HPLC-UV	99.78%
Net Content		GHK-Cu - 55.24 mg, KPV - 10.78 mg, BPC-157 - 10.24 mg, Thymosin Beta-4 - 10.58 mg

Chromatogram

Mass confirmation

Download COA (PDF)

Why Source from 321 Peptides?

Four domestically produced components.

Every KLOW ingredient is manufactured and finished in GMP-certified California and Arizona facilities, never sourced from overseas or Mexico.

A formula you can verify.

Third-party HPLC evaluates each ≥99% component purity target, while mass spectrometry confirms identity. One batch-specific COA documents the exact 50/10/10/10mg composition.

One lyophilized research vial.

Freeze-drying helps protect all four compounds during storage and transit. Domestic fulfillment reduces handling time and strengthens accountability.

Lot history 4 released lots

Every batch released under this compound, with the figure reported for each.

Lot	Reported	Purity	Net content	COA
KLO432	2026-06-01	99.78%	GHK-Cu - 55.24 mg, KPV - 10.78 mg, BPC-157 - 10.24 mg, Thymosin Beta-4 - 10.58 mg	PDF
KL-59812 Superseded	2026-05-12	99.52%	80.56 mg	Pending
KL-58658 Superseded	2026-05-06	99.88%	80.40 mg	Pending
KL-59235 Superseded	2026-05-02	99.71%	80.48 mg	Pending

Frequently Asked Questions

What is in KLOW Blend 80mg?

KLOW contains GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg. The four components total 80mg per research vial.

What pathways does KLOW Blend target in research?

Its components are studied across copper and matrix signaling, vascular and nitric-oxide pathways, actin-related cell behavior, and NF-κB/MAPK signaling. The blend does not establish a proven human effect.